Ohio State University Comprehensive Cancer Center

The Ohio State University Cancer Research Center was established in 1973 and received National Cancer Institute designation in April 1976 as a comprehensive cancer center (OSUCCC). The patient care arm of the OSUCCC is the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. The center is known as the OSUCCC – James.

The OSUCCC – James is a founding member of the National Comprehensive Cancer Network (NCCN), an alliance of 21 leading cancer centers that develops clinical practice guidelines to improve the quality of care.

The concentration of cancer research and patient care at the OSUCCC has led the OSUCCC – James to become one of only a few cancer centers awarded contracts by the NCI to conduct both phase I and phase II clinical trials on new NCI-sponsored anticancer drugs. Those trials take place in inpatient and outpatient facilities at the center.

Active Therapeutic Thoracic Trials – December 2017 include:

    • Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
    • Phase III, Double – Blind Trial for Surgically Resected Early Stage, Non – Small Cell Lung Cancer: Crizotinib vs. Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase Fusion Protein
    • Open – Label, Randomized, Phase III Trial of Nivolumab or Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy vs. Platinum Doublet Chemotherapy in Subjects With Chemotherapy – Naïve Stage IV or Recurrent Non – Small Cell Lung Cancer
    • Phase II, Open – Label, Multicenter, Single – Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients With Stage IB, II or IIIA Resectable and Untreated Non – Small Cell Lung Cancer
    • Phase III, Randomized, Open – Label Study of Lorlatinib (PF – 06463922) Monotherapy vs. Crizotinib Monotherapy in the First – Line Treatment of Patients With Advanced ALK – Positive Non – Small Cell Lung Cancer
    • Lung – MAP: Biomarker – Targeted Second – Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Learn more